TiGenix: Positive Interim Safety Results of Phase IIa Rheumatoid Arthritis Study With Allogeneic Adult Stem Cells …
LEUVEN, BELGIUM and MADRID, SPAIN--(Marketwire - Dec 19, 2012) - TiGenix ( EURONEXT BRUSSELS : TIG ), the European leader in cell therapy, announced today positive interim safety results of its Phase IIa study of Cx611 in rheumatoid arthritis (RA). Cx611 is an intravenously injected suspension of expanded allogeneic adult stem cells derived from human adipose (fat) tissue. The Phase IIa clinical trial is a 53-subject, multicenter, placebo-controlled study in 3 cohorts with different dosing regimens, designed to assess safety, feasibility, tolerance, and optimal dosing. The study is being conducted at 23 centers. The Company believes that this clinical trial can set the stage not only for the further development of Cx611 in RA, but also in a wide range of other autoimmune disorders.
The interim results cover the first three months of the Phase IIa's six-month follow-up, and the data are still blinded. The primary endpoint of this study is safety, and the data collected so far support the good safety profile of all three doses of Cx611. Only two patients (4%) have suffered serious adverse events and only in one case (2%) it led to discontinuation of the treatment. All other side effects were mild and transient.
"We are delighted to report that the safety profile of Cx611 appears to be excellent," said Eduardo Bravo, CEO of TiGenix. "We have recruited patients who have failed at least two biologicals. If, in addition to this promising safety data, we can demonstrate a first indication of efficacy in this difficult to treat patient population, we will have a strong rationale to move forward with this product. We are looking forward to reporting the final results of the study at the end of April 2013."
About TiGenix
TiGenix NV ( EURONEXT BRUSSELS : TIG ) is a leading European cell therapy company with a marketed product for cartilage repair, ChondroCelect, and a strong pipeline with clinical stage allogeneic adult stem cell programs for the treatment of autoimmune and inflammatory diseases. TiGenix is based out of Leuven (Belgium) and has operations in Madrid (Spain), and Sittard-Geleen (the Netherlands). For more information please visit http://www.tigenix.com.
Forward-looking informationThis document may contain forward-looking statements and estimates with respect to the anticipated future performance of TiGenix and the market in which it operates. Certain of these statements, forecasts and estimates can be recognised by the use of words such as, without limitation, "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will" and "continue" and similar expressions. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond TiGenix' control. Therefore, actual results, the financial condition, performance or achievements of TiGenix, or industry results, may turn out to be materially different from any future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of the publication of this document. TiGenix disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in TiGenix' expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by Belgian law.
See the original post here:
TiGenix: Positive Interim Safety Results of Phase IIa Rheumatoid Arthritis Study With Allogeneic Adult Stem Cells ...
Recommendation and review posted by Bethany Smith
Gene find may mean new cancer drugs
A gene network has been uncovered that could unlock the door to completely new treatments for advanced prostate cancer.
The discovery shows how genes previously not linked to the disease are activated in cancers that have become resistant to hormone treatment.
Scientists identified potential new drug targets and markers that could be used to track cancer progression.
Prostate cancer is fuelled by male hormones via a protein molecule called the androgen receptor. Standard treatment includes drugs that stop androgen hormones such as testosterone acting on prostate tumours, or cut off their supply.
But in time, the drugs stop working as the cancer overcomes its dependency on external androgens. Previous studies show how the androgen receptor attaches to and switches on specific genes to drive cancer.
The new research reveals that in tumours that are resistant to hormone therapy, the receptor activates a completely different set of genes including some associated with the production of sugar and fat.
Each year up to 41,000 men in the UK are diagnosed with prostate cancer each year and around 10,700 die from the disease. Scientists at Cambridge University made the discovery after looking at tissue samples from men with prostate cancer. The findings are published in the journal Cancer Cell.
Study leader Naomi Sharma, from the Cancer Research UK Cambridge Research Institute, said: "Our understanding so far comes from studies in cells grown in the laboratory. In this sophisticated study using samples directly from patients, we've uncovered a much more complex network of cell messages.
"These messages switch on a completely different set of genes that continue to drive the disease in men for whom standard hormone treatments have stopped working.
"These important findings provide fresh targets for the development of new drugs to treat advanced stages of prostate cancer, and new 'flags' to help doctors track the progression of the disease in patients."
Read more:
Gene find may mean new cancer drugs
Recommendation and review posted by Bethany Smith
Global Transfection (Gene Delivery, DNA Delivery, Protein Delivery, SiRNA Delivery) Technologies (Lipofection, Calcium …
NEW YORK, Dec. 19, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Transfection is an enabler technology used for many cell based research activities with applications spanning production of recombinant proteins and recombinant cell lines, gene therapy, delivery of therapeutics and also drug discovery. This research report provides a brief description on transfection technologies, its evolution, comparative analysis, market landscape analysis, competitive scenario and emerging technology and application trends. Global research and development Network, Innovation and Spin offs have been discussed. The report tracks regional adoption and development trends, providing strategic recommendation to stay active and compete in the market space. An impact analysis of major drivers and restraints influencing the growth of the market is mapped for five year period.
Cell research is a major driving factor for transfection market, as more than 60% of the users are of academic institutions and researchers. Research in gene transfer is being performed in in vivo conditions for different therapeutic applications; there is a growing demand for new transfection technologies to address unmet needs for therapeutic delivery which is driving the transfection market.
Key Restraint:
Home brewReagents restricts sale of commercial kits
Home brew reagents are still the preferred choice of reagents for transfection by researchers all over the world. Most of the researchers prepare their own reagents from their laboratory to conduct their research. This is true for most of the reagent based transfection reactions. This allows them to reduce cost involved in purchasing commercial kits.
Transfection is an enabler technology which is used in many cell research activities, however only few cell lines are majorly used in these experiments restricting the scope of the study. Transfection in hard to transfect cells is the need of hour and it is a major challenge. There are few upcoming transfection technologies like nucleofection and magnetofection which are an off-shoot of electroporation, which have the potential to address these challenges but are currently cost prohibitive due to which the technologies may have a much slower uptake in the developing world.
The report also discusses new opportunities for investment in the upcoming areas like Gene therapy, Stem cell research and Electro-chemotherapy.
Different transfection technologies are analyzed through a multi-criteria based decision making process which provides competitive benchmarking. Further, the report analyses technology management strategies and technology road mapping for the forecast period. Profiles of over 20 Key companies in the area of Transfection technology sector have been provided. Key players include Life Technologies, Sigma Aldrich, Lonza, Promega, Qiagen, Bio-Rad, Roche, Polyplus Transfection, Mirius Bio, Maxcyte, etc.
Read more from the original source:
Global Transfection (Gene Delivery, DNA Delivery, Protein Delivery, SiRNA Delivery) Technologies (Lipofection, Calcium ...
Recommendation and review posted by Bethany Smith
OpGen Announces Partnership with University of California, Davis, to Develop High Resolution Microbial Genetic Maps in …
GAITHERSBURG, Md.--(BUSINESS WIRE)--
OpGen, Inc. today announced the company has entered into a scientific and technical partnership with the University of California, Davis, (UC Davis) in cooperation with the FDA supported 100K Genome Project to create high resolution microbial genetic maps.
The 100K Genome Project is a collaboration that was initiated by the U.S. Food and Drug Administration (FDA), UC Davis, and Agilent Technologies to sequence the genetic code of at least 100,000 infectious organisms and accelerate the diagnosis of foodborne illnesses. UC Davis will integrate OpGens Argus Whole Genome Mapping System into its current DNA sequencing workflow for sequence assembly and validation of the genomes.
Through the integration of OpGens Whole Genome Mapping technology, The 100K Genome Project will create a new gold standard for high-quality microbial reference genomes. These data will be used in the surveillance and management of international foodborne microbial outbreaks, and to establish a high-fidelity global reference database for microbial genomes. The 100K Genome Project will publish the genomes that are completed and validated using OpGens Whole Genome Maps to a database, providing access to the genomic maps for public health agencies throughout the world. The FDA is advocating rigorous quality control standards for this reference database whereby genomic information should be validated by two independent methods.
OpGens technology allows us to complete sequencing and provide quality control of genomes drafted by data produced using short read next-generation sequencing methods, said Bart C. Weimer, Ph.D., Professor, Department of Population and Reproduction, School of Veterinary Medicine, University of California, Davis, and Director of The 100K Pathogen Genome Project. Whole Genome Mapping provides an independent method to detect sequence variations and misassemblies, and aids us in closing the gaps. Final Whole Genome Maps will assist health agencies in outbreak management of food borne diseases which cause tremendous risk to public health.
We are pleased to be a partner in this collaboration with UC Davis and the FDA in helping to set a high-quality, validated standard for this important reference database of microbes, which pose the greatest threats to food safety and public health, said Douglas White, Chief Executive Officer of OpGen. OpGen is committed to advancing public health and providing actionable information to the healthcare community.
The Centers for Disease Control and Prevention (CDC) estimates that each year roughly one in six Americans (or 48 million people) become sick, 128,000 are hospitalized, and 3,000 die of foodborne diseases.1 There are 31 known foodborne pathogens, including Salmonella, Listeria, and E. coli, among others.1 Many of these pathogens are tracked by public health systems that track diseases and outbreaks.1 Rapid identification and detection of these pathogens can lead to more effective control and management of microbial disease outbreaks.
About ArgusWhole Genome Mapping System
OpGens Argus Whole Genome Mapping System is the only commercially available technology that can provide a high-resolution, complete visual map of a whole genome and individual chromosomes. The companys unique single molecule analysis technology provides a whole genome view that complements genome assembly and enables scientists to identify highly repetitive regions, tandem repeats and translocations that are very difficult to identify and clarify with sequencing alone. Sequencing projects can now be finished and validated with less investment in time, cost and computational effort.
About OpGen, Inc.
See more here:
OpGen Announces Partnership with University of California, Davis, to Develop High Resolution Microbial Genetic Maps in ...
Recommendation and review posted by Bethany Smith
United States In Vitro Diagnostics Market Outlook to 2018- Clinical Chemistry Genetic Testing, Haematology, Histology …
NEW YORK, Dec. 20, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
United States In Vitro Diagnostics Market Outlook to 2018- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
Scope
- Market size and company share data for In Vitro Diagnostics market categories Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture.- Annualized market revenues (USD million) data for each of the segments and sub-segments within seven market categories. Data from 2004 to 2011, forecast forward for 7 years to 2018. - 2011 company shares and distribution shares data for each of the seven market categories.- Global corporate-level profiles of key companies operating within the United States In Vitro Diagnosticsmarket. - Key players covered include Siemens Healthcare, Abbott Laboratories, F. Hoffmann-La Roche Ltd., Beckman Coulter, Inc., Ortho-Clinical Diagnostics Inc., Alere Inc. and others.
Reasons to buy
- Develop business strategies by identifying the key market categories and segments poised for strong growth.- Develop market-entry and market expansion strategies.- Design competition strategies by identifying who-stands-where in the United States In Vitro Diagnostics competitive landscape.- Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.- What are the key distribution channels and what's the most preferred mode of product distribution Identify, understand and capitalize.1 Table of Contents1 Table of Contents 21.1 List of Tables 71.2 List of Figures 132 Introduction 162.1 What is This Report About? 163 In Vitro Diagnostics In United States 173.1 In Vitro Diagnostics, Market Segmentation 173.2 In Vitro Diagnostics, United States, Overall Revenue ($m), USD Constant, 2004-2018 183.3 In Vitro Diagnostics Market, United States, Revenue Mix ($m), 2011 203.4 In Vitro Diagnostics Market, United States, Category Contribution (%), 2011 213.5 In Vitro Diagnostics, United States, Company Share (2010-2011) 284 Clinical Chemistry In United States 304.1 Clinical Chemistry, Market Segmentation 304.2 Clinical Chemistry Market, United States, Revenue Mix ($m), 2011 314.3 Clinical Chemistry Market, United States, Segment Contribution (%), 2011 324.4 Clinical Chemistry Overall Revenue, (2004-2018) 334.5 Clinical Chemistry Distribution Share (2010-2011) 454.6 Clinical Chemistry, United States, Company Share (2010-2011) 465 Genetic Testing In United States 475.1 Genetic Testing, Market Segmentation 475.2 Genetic Testing Market, United States, Revenue Mix ($m), 2011 485.3 Genetic Testing Market, United States, Segment Contribution (%), 2011 495.4 Genetic Testing Overall Revenue, (2004-2018) 505.5 Genetic Testing Distribution Share (2010-2011) 545.6 Genetic Testing, United States, Company Share (2010-2011) 556 Haematology In United States 576.1 Haematology Market, Market Segmentation 576.2 Haematology Market, United States, Revenue Mix ($m), 2011 586.3 Haematology Market, United States, Segment Contribution (%), 2011 596.4 Haematology Overall Revenue, (2004-2018) 606.5 Haematology Distribution Share (2010-2011) 846.6 Haematology, United States, Company Share (2010-2011) 857 Histology And Cytology In United States 877.1 Histology and Cytology Market, Market Segmentation 877.2 Histology And Cytology Market, United States, Revenue Mix ($m), 2011 887.3 Histology And Cytology Market, United States, Segment Contribution (%), 2011 897.4 Histology And Cytology Overall Revenue, (2004-2018) 907.5 Histology And Cytology Distribution Share (2010-2011) 947.6 Histology And Cytology, United States, Company Share (2010-2011) 958 Immuno Chemistry In United States 978.1 Infectious Immunology, Market Segmentation 978.2 Immuno Chemistry Market, United States, Revenue Mix ($m), 2011 988.3 Immuno Chemistry Market, United States, Segment Contribution (%), 2011 998.4 Immuno Chemistry Overall Revenue, (2004-2018) 1008.5 Immuno Chemistry Distribution Share (2010-2011) 1288.6 Immuno Chemistry, United States, Company Share (2010-2011) 1299 Infectious Immunology In United States 1319.1 Infectious Immunology Market, United States, Revenue Mix ($m), 2011 1319.2 Infectious Immunology Market, United States, Segment Contribution (%), 2011 1329.3 Infectious Immunology Overall Revenue, (2004-2018) 1339.4 Infectious Immunology Distribution Share (2010-2011) 1419.5 Infectious Immunology, United States, Company Share (2010-2011) 14210 Microbiology Culture In United States 14410.1 Microbiology Culture, Market Segmentation 14410.2 Microbiology Culture Market, United States, Revenue Mix ($m), 2011 14510.3 Microbiology Culture Market, United States, Segment Contribution (%), 2011 14610.4 Microbiology Culture Overall Revenue, (2004-2018) 14710.5 Microbiology Culture Distribution Share (2010-2011) 15510.6 Microbiology Culture, United States, Company Share (2010-2011) 15611 Overview of Key Companies in United States In Vitro Diagnostics Market 15811.1 Siemens Healthcare 15811.2 Abbott Laboratories 15911.3 F. Hoffmann-La Roche Ltd. 16011.4 Beckman Coulter, Inc. 16111.5 Ortho-Clinical Diagnostics Inc. 16211.6 Alere Inc. 16311.7 Danaher Corporation 16411.8 bioMerieux S.A. 16411.9 Becton, Dickinson and Company 16511.10 Bio-Rad Laboratories, Inc. 16511.11 Sysmex Corporation 16611.12 Qiagen N.V. 16611.13 Gen-Probe Incorporated 16711.14 DiaSorin S.p.A 16711.15 Immucor, Inc. 16811.16 Cepheid 16811.17 Thermo Fisher Scientific Inc. 16911.18 Hologic, Inc. 16911.19 PerkinElmer, Inc. 17011.20 Grifols, S.A. 17011.21 Olympus Corporation 17111.22 Horiba, Ltd. 17111.23 Life Technologies Corporation 17211.24 Diagnostica Stago, Inc. 17211.25 ELITech Group 17311.26 OraSure Technologies, Inc. 17312 In Vitro Diagnostics Market Pipeline Products 17412.1 Clinical Chemisty Market Pipeline Products 17412.2 Immuno Chemistry Market Pipeline Products 18112.3 Haematology Market Pipeline Products 19212.4 Infectious Immunology Market Pipeline Products 19412.5 Microbiology Culture Market Pipeline Products 20112.6 Histology And Cytology Market Pipeline Products 20212.7 Genetic Testing Market Pipeline Products 20313 Financial Deals Landscape 20813.1 Acquisition 20813.2 Partnerships 23914 Recent Developments 33014.1 Strategy And Business Planning 33014.2 Research And Development 35314.3 Legal and Regulatory 35914.4 Government and Public Interest 38114.5 Product News 42815 Appendix 52515.1 Definitions of Markets Covered in the Report 52615.2 Research Methodology 53715.3 Secondary Research 53715.4 Primary Research 53815.5 Models 53815.6 Forecasts 53915.7 Expert Panels 53915.8 GlobalData Consulting 53915.9 Contact Us 54015.10 Disclaimer 540
List of Tables
Table 1: In Vitro Diagnostics, United States, Overall Revenue ($m), USD Constant, 2004-2018 36Table 2: In Vitro Diagnostics Market, United States, Category Contribution (%), 2011 38Table 3: In Vitro Diagnostics Market, United States, Cross-Category Analysis, 2004-2018 40Table 4: In Vitro Diagnostics, United States, Overall Revenue ($m), USD Constant, Historic, 2004-2011 42Table 5: In Vitro Diagnostics, United States, Overall Revenue ($m), USD Constant, Forecast, 2011-2018 44Table 6: In Vitro Diagnostics, United States, Company Share by Revenue ($m), USD Constant, 2010-2011 46Table 7: Clinical Chemistry Market, United States, Segment Contribution (%), 2011 49Table 8: Clinical Chemistry, United States, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 51Table 9: Clinical Chemistry, United States, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 53Table 10: Clinical Chemisty Analyzers, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 55Table 11: Clinical Chemisty Analyzers, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 57Table 12: Urine Analysis, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 59Table 13: Urine Analysis, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 61Table 14: Clinical Chemistry, United States, Distribution Share by Revenue ($m), USD Constant, 2010-2011 62Table 15: Clinical Chemistry, United States, Company Share by Revenue ($m), USD Constant, 2010-2011 63Table 16: Genetic Testing Market, United States, Segment Contribution (%), 2011 66Table 17: Genetic Testing, United States, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 68Table 18: Genetic Testing, United States, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 70Table 19: Genetic Testing, United States, Distribution Share by Revenue ($m), USD Constant, 2010-2011 71Table 20: Genetic Testing, United States, Company Share by Revenue ($m), USD Constant, 2010-2011 73Table 21: Haematology Market, United States, Segment Contribution (%), 2011 76Table 22: Haematology, United States, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 78Table 23: Haematology, United States, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 80Table 24: Haematology Reagents, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 82Table 25: Haematology Reagents, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 84Table 26: Immunohaematology, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 86Table 27: Immunohaematology, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 88Table 28: Haemostasis, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 90Table 29: Haemostasis, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 92Table 30: Haematology Rapid Tests, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 94Table 31: Haematology Rapid Tests, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 96Table 32: Haematology Cell Counters, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 98Table 33: Haematology Cell Counters, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 100Table 34: Haematology, United States, Distribution Share by Revenue ($m), USD Constant, 2010-2011 101Table 35: Haematology, United States, Company Share by Revenue ($m), USD Constant, 2010-2011 103Table 36: Histology And Cytology Market, United States, Segment Contribution (%), 2011 106Table 37: Histology And Cytology, United States, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 108Table 38: Histology And Cytology, United States, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 110Table 39: Histology And Cytology, United States, Distribution Share by Revenue ($m), USD Constant, 2010-2011 111Table 40: Histology And Cytology, United States, Company Share by Revenue ($m), USD Constant, 2010-2011 113Table 41: Immuno Chemistry Market, United States, Segment Contribution (%), 2011 116Table 42: Immuno Chemistry, United States, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 118Table 43: Immuno Chemistry, United States, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 120Table 44: Disease Specific Immunochemistry, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 122Table 45: Disease Specific Immunochemistry, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 124Table 46: Drugs of Abuse / Toxicology, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 126Table 47: Drugs of Abuse / Toxicology, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 128Table 48: Endocrinology Tests, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 130Table 49: Endocrinology Tests, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 132Table 50: Immunochemistry Rapid Tests, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 134Table 51: Immunochemistry Rapid Tests, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 136Table 52: Therapeutic Drug Monitoring, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 138Table 53: Therapeutic Drug Monitoring, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 140Table 54: Immunochemistry Analyzers, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 142Table 55: Immunochemistry Analyzers, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 144Table 56: Immuno Chemistry, United States, Distribution Share by Revenue ($m), USD Constant, 2010-2011 145Table 57: Immuno Chemistry, United States, Company Share by Revenue ($m), USD Constant, 2010-2011 147Table 58: Infectious Immunology Market, United States, Segment Contribution (%), 2011 149Table 59: Infectious Immunology, United States, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 151Table 60: Infectious Immunology, United States, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 153Table 61: Infectious Immunology Rapid Tests, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 155Table 62: Infectious Immunology Rapid Tests, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 157Table 63: Infectious Immunology, United States, Distribution Share by Revenue ($m), USD Constant, 2010-2011 158Table 64: Infectious Immunology, United States, Company Share by Revenue ($m), USD Constant, 2010-2011 160Table 65: Microbiology Culture Market, United States, Segment Contribution (%), 2011 163Table 66: Microbiology Culture, United States, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 165Table 67: Microbiology Culture, United States, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 167Table 68: Microbiology Analyzers, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 169Table 69: Microbiology Analyzers, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 171Table 70: Microbiology Culture, United States, Distribution Share by Revenue ($m), USD Constant, 2010-2011 172Table 71: Microbiology Culture, United States, Company Share by Revenue ($m), USD Constant, 2010-2011 174Table 72: Clinical Chemisty Market Pipeline Products 191Table 73: Immuno Chemistry Market Pipeline Products 198Table 74: Haematology Market Pipeline Products 209Table 75: Infectious Immunology Market Pipeline Products 211Table 76: Microbiology Culture Market Pipeline Products 218Table 77: Histology And Cytology Market Pipeline Products 219Table 78: Genetic Testing Market Pipeline Products 220Table 79: ERBA Diagnostics Acquires Drew Scientific, Maker Of Analytical Instruments And Reagents, For $6.5 Million 225Table 80: Measurement Specialties Acquires Cambridge Technologies And Resistance Temperature Detector Company For $18.8 Million 227Table 81: Atossa Genetics Acquires Acueity Healthcare, Diagnostic Device Provider 228Table 82: AccelPath Acquires DigiPath Solutions For $2.4 Million 229Table 83: Danaher Completes Acquisition Of 91.6% Stake In Iris International, Diagnostic Test Maker, For $324 Million 230Table 84: Charles River Labs Acquires Accugenix, Provider Of Microbe Identification Services, For $17 Million 232Table 85: Leica Biosystems Completes Acquisition Of Aperio Technologies 233Table 86: Metabolon Acquires Lipomics Technologies, Diagnostics Company 235Table 87: Waters Acquires Blue Reference, Maker Of Application Scientific Databases, For $14 Million 237Table 88: Life Technologies Acquires Pinpoint Genomics, Molecular Diagnostics Company 238Table 89: Thermo Fisher Scientific Completes Acquisition Of One Lambda, Transplant Diagnostics Company, For $925 Million 239Table 90: Life Technologies Acquires Navigenics 241Table 91: Genova Diagnostics Acquires Metametrix, Clinical Laboratory 243Table 92: Luminex To Acquire GenturaDx, Molecular Diagnostics Company, For $50 Million 244Table 93: Systagenix Acquires O2 Insights 246Table 94: LabCorp Completes Acquisition Of Medtox Scientific For $241 Million 247Table 95: Flagship Biosciences Acquires Ihctech, Provider Of Research Immunohistochemistry And Histology Services 249Table 96: Halo Healthcare Acquires NeoMatrix, Maker Of Diagnostic Equipments 250Table 97: Qiagen Acquires AmniSure International, Manufacturer Of Non Invasive Test Solutions 251Table 98: Hologic Completes Acquisition Of Gen-Probe For $3.7 Billion 252Table 99: Haemonetics To Acquire Hemerus Medical, Provider Of Leukoreduction Technologies, For $27 Million 254Table 100: IntegenX Acquires SV, Provider Of DNA Identification Consumable Products, From GE Healthcare Bio-Sciences 255Table 101: DioGenix Enters Into Agreement With Fast Forward To Develop New Blood Test For Multiple Sclerosis 256Table 102: GNS Healthcare Enters Into Agreement With Dana-Farber Cancer Institute and Mount Sinai School of Medicine 257Table 103: Crown Bioscience Enters Into Co-Development Agreement With Horizon Discovery 259Table 104: CombiMatrix Enters Into Co-Marketing Agreement With Pathology For Prenatal Tests 260Table 105: Clinical Genomics Enters Into Licensing Agreement With Quest Diagnostics For Colon Cancer Markers 261Table 106: Abaxis Enters Into Distribution Agreement With Abbott Point of Care For Piccolo Blood Chemistry System 262Table 107: Malvern Instruments Enters Into Co-Marketing Agreement With Affinity Biosensors For Archimedes Particle Metrology System 263Table 108: Exosome Diagnostics Enters Into Co-Development Agreement With Promega For Urine Clinical Sample Concentrator Kit 264Table 109: Agenix Enters Into Licensing Agreement With Tyrian Diagnostics For DiagnostIQ 265Table 110: Ezose Enters Into Co-Development Agreement With Fast Forward For Multiple Sclerosis Biomarkers 266Table 111: BioDot Enters Into Co-Marketing Agreement With JOT Automation 267Table 112: Sequella Enters Into Licensing Agreement With LabCorp For B-Smart Technology 268Table 113: LifeTech Scientific, DiNova Venture Partners, Themes Investment Partners And Broncus Technologies Partner To Form Broncus Medical 269Table 114: Van Andel Institute Enters Into Co-Development Agreement With Emory University 270Table 115: Merck Serono Enters Into Co-Development Agreement With Auxogyn For Early Embryo Viability Assessment Test 271Table 116: PGXL Labs Enters Into Joint Venture Agreement With Essential Molecular Testing 272Table 117: Broad Institute Enters Into Distribution Agreement With Appistry For Genome Analysis Toolkit 273Table 118: Thermo Fisher Enters Into Co-Development Agreement With Immundiagnostik 274Table 119: Sage Labs Enters Into Agreement With Ekam Imaging To Develop Imaging Assays 275Table 120: Bruker Enters Into An Agreement With Nextval For High-throughput Screening Technology 276Table 121: BD Diagnostic Systems Enters Into Agreement With Lab21 To Develop New Oncology Assays 277Table 122: RainDance Technologies Enters Into Co-Development Agreement With Integrated DNA Technologies For Digital PCR 278Table 123: Amarantus BioSciences Enters Into Option For Licensing Agreement With Memory Dx For LymPro Blood Test 279Table 124: Iverson Genetic Diagnostics Enters Into Licensing Agreement With Johns Hopkins University School For Molecular Diagnostic Tests 280Table 125: Rosetta Genomics Amends Co-Marketing Agreement With Precision Therapeutics For miRview mets2 Assays 281Table 126: Mitomics Enters Into Co-Marketing Agreement With LabCorp For Prostate Core Mitomic Test 282Table 127: Trillium Diagnostics Enters Into Licensing Agreement With Leukocare For Sepsis Dx 283Table 128: Foundation Medicine Enters Into Agreement With Eisai For Genomic Profiling And Diagnostic Discovery 284Table 129: Vela Diagnostics Enters Into Licensing Agreement With Life Technologies 285Table 130: Augurex Life Sciences Enters Into Licensing Agreement With Quest Diagnostics For 14-3-3n Biomarker 286Table 131: CellaVision Enters Into Distribution Agreement With Siemens Healthcare For Digital Microscopy Hematology Solutions 287Table 132: Ingenuity Systems Enters Into Co-Development Agreement With Life Technologies For Diagnostic Solutions 288Table 133: Med BioGene Amends Licensing Agreement With Precision Therapeutics For LungExpress Dx Test 290Table 134: Genia Technologies Enters Into Co-Development Agreement With Columbia University And Harvard University 292Table 135: NextBio Enters Into Agreement With Winship Cancer Institute of Emory University For Myeloma Biomarkers 294Table 136: Ovizio Imaging Systems Enters Into Distribution Agreement With Applikon Biotechnology 295Table 137: Atossa Enters Into Co-Marketing Agreement With Diagnostics Test Group For MASCT System 296Table 138: Genalyte Partners Scienion To Provide Sciflexarrayer Dispensers For Maverick Detection Platform 297Table 139: CML HealthCare Enters Into Agreement With MaRS Innovation 298Table 140: Life Technologies Enters Into Agreement With Bristol-Myers Squibb For Companion Diagnostics Development 299Table 141: Agilent Technologies Enters Into Co-Marketing Agreement With Molecular Discovery 300Table 142: Agilent Technologies Enters Into Co-Marketing Agreement With MRM Proteomics 301Table 143: Castle Biosciences Enters Into Licensing Agreement With Brigham and Women's Hospital For Mesothelioma Test 302Table 144: Illumina Enters Into Technology Integration Agreement With Partners HealthCare System 303Table 145: Scienion Enters Into Co-Marketing Agreement With Maine Manufacturing For Protein Array Products 304Table 146: ImaginAb Enters Into Co-Development Agreement With MacroGenics 305Table 147: BellBrook Labs Enters Into Co-Development Agreement With Reaction Biology 306Table 148: GVK Biosciences Enters Into Licensing Agreement With National Cancer Institute For GOBIOM Database 307Table 149: GeneCentric Diagnostics Enters Into Licensing Agreement With University of North Carolina 308Table 150: Perkinelmer Enters Into Co-Development Agreement With Massachusetts General Hospital 309Table 151: Affymetrix Enters Into Co-Development Agreement With Pathgen Dx 310Table 152: Axela Enters Into Co-Marketing Agreement With OvaGene Oncology 311Table 153: University of Michigan Enters Into Joint Venture Agreement With International Genomics Consortium 312Table 154: Regulus Therapeutics Enters Into An Agreement With Biogen Idec For Biomarkers 313Table 155: Curetis Enters Into Licensing Agreement With Cempra For Unyvero 314Table 156: Foundation Medicine Enters Into Co-Development Agreement With Clovis Oncology 315Table 157: Saladax Biomedical Expands Co-Development Agreement With Bristol-Myers Squibb 316Table 158: Epistem Enters Into Distribution Agreement With Becton Dickinson For Mycobacterium TB Test 317Table 159: Waters Enters Into Co-Development Agreement With Nonlinear Dynamics 318Table 160: Affymetrix Expands Licensing Agreement With Siemens Healthcare For Branched DNA Technology 319Table 161: Molecular Targeting Technologies Enters Into Licensing Agreement With Medical College of Wisconsin For 99mTc-HYNIC-Duramycin 320Table 162: Rosetta Genomics Enters Into Co-Marketing Agreement With Precision Therapeutics For miRview mets2 Assays 321Table 163: Bio-Rad Labs Enters Into Distribution Agreement With Myriad RBM For Multiplex Biomarker Kits 322Table 164: Gen-Probe Enters Into Co-Marketing Agreement With Life Technologies 323Table 165: OriGene Technologies Enters Into Co-Development Agreement With Centre of Excellence for Prevention of Organ Failure 324Table 166: Siemens Healthcare Diagnostics Enters Into Distribution Agreement With Sysmex 325Table 167: IRIS International Enters Into Distribution Agreement With Alifax 326Table 168: EKF Diagnostics Enters Into Licensing Agreement With Joslin Diabetes Center 327Table 169: SciFluor Life Sciences Enters Into Distribution Agreement With Sigma-Aldrich For PhenoFluor 328Table 170: Clovis Oncology Enters Into Co-Development Agreement With Array BioPharma 329Table 171: RS Medical Enters Into Distribution Agreement With Harvest Technologies 330Table 172: Immuno-Biological Labs Enters Into Licensing Agreement With IBL International 331Table 173: Sandia National Labs Plans To Enter Into Licensing Agreement For SpinDx, Medical Diagnostic Tool 332Table 174: HTG Molecular Diagnostics Enters Into Licensing Agreement With Merck For Breast Cancer Marker Patent Portfolio 333Table 175: Genisphere Enters Into Co-Development Agreement With Lankenau Institute for Medical Research 334Table 176: WaferGen Biosystems Enters Into Agreement With Integrated DNA Technologies 335Table 177: BioView Enters Into Co-Development Agreement With ScreenCell For Circulating Tumor Cell Analysis Technology 336Table 178: MDxHealth Enters Into Licensing Agreement With Merck For MGMT Diagnostic Test 337Table 179: Fluxion Biosciences Enters Into Co-Development Agreement With Stanford University School of Medicine 338Table 180: Merrimack Pharma Enters Into Co-Development Agreement With Cancer Treatment Centers of America 339Table 181: Phenomenome Discoveries Enters Into Licensing Agreement With Polymedco For Cancer Diagnostic Test 340Table 182: PlexPress Enters Into Technology Integration Agreement With Phalanx Biotech 341Table 183: PrimeraDx Enters Into Co-Development Agreement With Eli Lilly 342Table 184: Kreatech Diagnostics Enters Into Co-Development Agreement With Oridis Biomarkers For DNA-FISH Assays 343Table 185: Stratos Enters Into Co- Development Agreement With nanoMR 344Table 186: Guided Therapeutics Extends Licensing And Co-Development Agreement With Konica Minolta 345Table 187: Berg Pharma Enters Into Co-Development Agreement With Parkinson's Institute 346
Read the original here:
United States In Vitro Diagnostics Market Outlook to 2018- Clinical Chemistry Genetic Testing, Haematology, Histology ...
Recommendation and review posted by Bethany Smith
genetics @ tonic room 12/16/12 – Video
genetics @ tonic room 12/16/12
From:lizeduslapedusViews:1 0ratingsTime:07:07More inMusic
See more here:
genetics @ tonic room 12/16/12 - Video
Recommendation and review posted by Bethany Smith
genetics @ tonic room II 12/16/12 – Video
genetics @ tonic room II 12/16/12
From:lizeduslapedusViews:0 0ratingsTime:05:40More inMusic
Read the original:
genetics @ tonic room II 12/16/12 - Video
Recommendation and review posted by Bethany Smith
genetics @ tonic room III 12/16/12 – Video
genetics @ tonic room III 12/16/12
From:lizeduslapedusViews:0 0ratingsTime:08:45More inMusic
Link:
genetics @ tonic room III 12/16/12 - Video
Recommendation and review posted by Bethany Smith
Secret Revealed : LOSE FAT Quickly and Easily NOW with FAT LOSS FACTOR – Video
Secret Revealed : LOSE FAT Quickly and Easily NOW with FAT LOSS FACTOR
Fat Loss Factor Program Link - goo.gl BEING FAT is NOT genetic! True, your entire family may be overweight but it doesn #39;t mean that you have to be. There are success stories all the time of people overcoming their "genetics" and possibly increasing your chances of rapid fat loss. Just watch the TV show "The Biggest Loser" (Google it if you #39;ve never seen it) It is full of people who have overcome their "genetics". Want to know a sort of secret? Your genes do not control your weight... your lifestyle does. Your genes are like a light switch, you can turn them on and off depending what you do with your life. Don #39;t be a victim of yourself and everything that you hear! Fat Loss Factor Program Link - goo.glFrom:TheHealthyStuffViews:7 0ratingsTime:02:40More inHowto Style
Read this article:
Secret Revealed : LOSE FAT Quickly and Easily NOW with FAT LOSS FACTOR - Video
Recommendation and review posted by Bethany Smith
Fight To Party – The Genetics – Video
Fight To Party - The Genetics
Our second music video. Songs mixed by The Genetics. We do not own any of the material in the video, all credit goes to their rightful owners. Enjoy. http://www.facebook.comFrom:stormcrow20k10Views:1 0ratingsTime:04:14More inMusic
See more here:
Fight To Party - The Genetics - Video
Recommendation and review posted by Bethany Smith
LOSE WEIGHT FAST with FAT LOSS FACTOR – Honest Review – Video
LOSE WEIGHT FAST with FAT LOSS FACTOR - Honest Review
Fat Loss Factor Program Link - goo.gl BEING FAT is NOT genetic! True, your entire family may be overweight but it doesn #39;t mean that you have to be. There are success stories all the time of people overcoming their "genetics" and possibly increasing your chances of rapid fat loss. Just watch the TV show "The Biggest Loser" (Google it if you #39;ve never seen it) It is full of people who have overcome their "genetics". Want to know a sort of secret? Your genes do not control your weight... your lifestyle does. Your genes are like a light switch, you can turn them on and off depending what you do with your life. Don #39;t be a victim of yourself and everything that you hear! Fat Loss Factor Program Link - goo.glFrom:TheHealthyStuffViews:3 0ratingsTime:03:22More inHowto Style
Follow this link:
LOSE WEIGHT FAST with FAT LOSS FACTOR - Honest Review - Video
Recommendation and review posted by Bethany Smith
Dentist in Austin | Ridge Preservation | Restoring Bone for Denture Patients – Video
Dentist in Austin | Ridge Preservation | Restoring Bone for Denture Patients
When you need to have a tooth or teeth extracted mdash;whether it be due to decay, abscess, gum disease or injury mdash;it is usually in your best interest to do so in a manner which preserves as much of your underlying jawbone as possible. From the time the teeth are removed, significant degeneration of the surrounding bone begins to take place. The amount of shrinkage is unpredictable. Many times the amount of remaining bone shrinks rapidly at first, followed by a more slowly progressing shrinking that occurs over the years afterwards. This shrinking is a natural process, but it is an undesirable result of tooth removal. You have many options to prevent the rapid initial loss of bone, and it is important that you consider them BEFORE any teeth are removed. Some of these procedures are best performed at the time the tooth is removed. To minimize the rapid shrinking of bone, a bone graft can be placed in the socket at the time of tooth removal. This type of bone graft is straightforward and produces little or no discomfort. A ridge preservation bone graft can often prevent the need for major bone grafting later on. Therefore, a ridge preservation bone graft helps to minimize the need for treatment with major bone grafting in the future. The slowly progressive shrinking that happens over time is really only prevented by replacing the missing tooth with a dental implant. The pace of this "slow" bone loss is difficult to predict and is influenced by the genetics of the patient. WHAT ...From:austinsdentistViews:0 0ratingsTime:01:12More inPeople Blogs
Go here to see the original:
Dentist in Austin | Ridge Preservation | Restoring Bone for Denture Patients - Video
Recommendation and review posted by Bethany Smith
1200w Veg Room – Next Round 8k Flower Room – Video
1200w Veg Room - Next Round 8k Flower Room
Hey guys. Wanted to shoot a quick video of the next round of girls that will be going into the BRAND NEW FRESHLY BUILT 8k FLOWER ROOM. Im sooo stoked for this next round... got some GREAT genetics goin in this time around. I say all the strains in the video but it gets kinda muffled so I will list them down below. Im not sure on how many weeks I veg for or am gonna veg for. It is usually between 6-8 weeks. I will keep a weekly update journal of the 8k flower room once we have these girls flipped and bathing in HPS lighting... Should be a fun run... Stay tuned for 8000 watts of DANK!! STRAINS: Chem Reaper (x1) Purple Arrow (x2) Snowcap (x3) Roxanne (x5) ( local cross - Purple Berry x Vitamin D) Bubba Kush (x1) (from seed) Cheesecake (x2) (local cross - clone only now - romulan x shishkaberry) Camelot Kush (x2) Starfire (x2) (Stardog Bx x Fire Alien OG) Tora Bora (x4) UW/G-13 (x2)From:PNWGardenOfFunkViews:5 0ratingsTime:04:55More inEntertainment
See original here:
1200w Veg Room - Next Round 8k Flower Room - Video
Recommendation and review posted by Bethany Smith
Francine Ke (2012): Searching for the function of the Bcl-2 family member Bok – Video
Francine Ke (2012): Searching for the function of the Bcl-2 family member Bok
Walter and Eliza Hall Institute Wednesday seminar: 5 December 2012 Francine Ke PhD student Molecular Genetics of Cancer Walter and Eliza Hall InstituteFrom:WalterandElizaHallViews:0 0ratingsTime:51:33More inScience Technology
Read the original:
Francine Ke (2012): Searching for the function of the Bcl-2 family member Bok - Video
Recommendation and review posted by Bethany Smith
BSc Genetics at UCC: A Student’s Perspective with Audrey Dearing – Video
BSc Genetics at UCC: A Student #39;s Perspective with Audrey Dearing
You can find out more about our course here: http://www.ucc.ie Email us at genetics@ucc.ie or call +353 (0)21 490 2861From:UCCIrelandViews:9 0ratingsTime:02:12More inEducation
Read more from the original source:
BSc Genetics at UCC: A Student's Perspective with Audrey Dearing - Video
Recommendation and review posted by Bethany Smith
Free will: just an illusion? – Video
Free will: just an illusion?
Professor Joe Friggieri head of philosophy, University of Malta; poet; playwright; theatre director; three-times winner, National Literary Prize Dr Daniel Glaser head, special projects, public engagement, Wellcome Trust; honorary senior research fellow, Institute of Cognitive Neuroscience, University College London Neal Lawson chair, Compass; author, All Consuming; former adviser to Gordon Brown; co-editor, Progressive Century Dr Ellie Lee reader in social policy, University of Kent, Canterbury; director, Centre for Parenting Culture Studies Chair: Angus Kennedy head of external relations, Institute of Ideas; chair, IoI Economy Forum; convenor, The Academy Free will is at the root of our notions of moral responsibility, choice and judgment. It is at the heart of our conception of the human individual as an autonomous end in himself. Nevertheless, free will is notoriously hard to pin down. Philosophers have denied its existence on the basis that we are determined by the laws of nature, society or history, insisting there is no evidence of free will in the iron chain of cause and effect. Theologians have argued everything happens according to the will of God, not man. And yet, when we decide we want something and act on that, it certainly seems as if we are choosing freely. Are we just kidding ourselves? Some of the most profound contemporary challenges to the idea of free will come from neuroscientists, evolutionary psychologists and biologists. They argue we are ...From:battleofideasViews:1 0ratingsTime:01:15:27More inNews Politics
Visit link:
Free will: just an illusion? - Video
Recommendation and review posted by Bethany Smith
The Amazing Spider-Man – Episode 3 – Asylum Rescue – Video
The Amazing Spider-Man - Episode 3 - Asylum Rescue
Dr. Connors escapes from the mental asylum with the aid of Spider-Man. They head to Peter #39;s apartment where Connors can formulate the antidote to the virus. Gwen isn #39;t too happy about Connors being there since he killed her father while he was the Lizard. Despite these complications, Spidey must return to Oscorp to get Connor #39;s notes on cross-species genetics.From:ChubbStufViews:1 0ratingsTime:15:12More inGaming
Excerpt from:
The Amazing Spider-Man - Episode 3 - Asylum Rescue - Video
Recommendation and review posted by Bethany Smith
Gene Therapy Interview with Dr. Tolar – Video
Gene Therapy Interview with Dr. Tolar
information about gene therapyFrom:ketters29Views:7 0ratingsTime:06:01More inScience Technology
See the original post:
Gene Therapy Interview with Dr. Tolar - Video
Recommendation and review posted by Bethany Smith
I Am Legend Gene Therapy – Video
I Am Legend Gene Therapy
Gene Therapy in I Am LegendFrom:El ai ay emViews:1 0ratingsTime:03:48More inPeople Blogs
See the original post here:
I Am Legend Gene Therapy - Video
Recommendation and review posted by Bethany Smith
The Mind of David Pearce Part 13 – How to make biotech sound sexy? – Video
The Mind of David Pearce Part 13 - How to make biotech sound sexy?
The Fate of the Germline Genetic evolution is slow. Progress in artificial intelligence is fast. Only a handful of genes separate Homo sapiens from our hominid ancestors on the African savannah. Among our 23000-odd protein-coding genes, variance in single nucleotide polymorphisms ("SNPs") accounts for just a small percentage of phenotypic variance in intelligence as measured by what we call IQ tests. True, the tempo of human evolution is about to accelerate. As the reproductive revolution of "designer babies" gathers pace, prospective parents will pre-select alleles and allelic combinations for a new child in anticipation of their behavioural effects - a novel kind of selection pressure to replace the "blind" genetic roulette of natural selection. In time, routine embryo screening via preimplantation genetic diagnosis will be complemented by gene therapy, genetic enhancement and then true designer zygotes. In consequence, life on Earth will also become progressively happier as the hedonic treadmill is recalibrated. In the new reproductive era, hedonic set-points and intelligence alike will be ratcheted upwards in virtue of selection pressure. For what parent-to-be wants to give birth to a low-status depressive "loser"? Future parents can enjoy raising a normal transhuman supergenius who grows up to be faster than Usain Bolt, more beautiful than Marilyn Monroe, more saintly than Nelson Mandela, more creative than Shakespeare - and smarter than Einstein. Even so, the ...From:AlgeKalipsoViews:0 0ratingsTime:01:24More inEntertainment
Here is the original post:
The Mind of David Pearce Part 13 - How to make biotech sound sexy? - Video
Recommendation and review posted by Bethany Smith
Gene Therapy podcast – Video
Gene Therapy podcast
From:BoyneatBradfordViews:0 0ratingsTime:58:34More inEducation
Continued here:
Gene Therapy podcast - Video
Recommendation and review posted by Bethany Smith
Gene Therapy, a new tool to cure human diseases – Video
Gene Therapy, a new tool to cure human diseases
Video created by UAB #39;s Centre for Animal Biotechnology and Gene Therapy (CBATEG) on gene therapy and the advances already achieved in disease treatments (which cannot be cured with traditional drugs), as well as the future of these treatments.From:UABBarcelonaViews:2 0ratingsTime:18:30More inEducation
Excerpt from:
Gene Therapy, a new tool to cure human diseases - Video
Recommendation and review posted by Bethany Smith
It Happened to Both of Us: Conversations with Couples – Video
It Happened to Both of Us: Conversations with Couples
When a person sustains a spinal cord injury, the impact is felt by the whole family, especially the spouse or partner. How does the partner feel, cope and adjust during this turbulent time when the injured person #39;s needs are so paramount? How do roles and expectations change? How can a couple survive the stresses and challenges of such a life-altering event and go on to lead a satisfying life together. In this video, a panel of couples who were together before injury and are still together talk about their experiences and what they do to stay connected and maintain a healthy relationship.From:UWSpinalCordInjuryViews:2 0ratingsTime:01:21:14More inScience Technology
Go here to read the rest:
It Happened to Both of Us: Conversations with Couples - Video
Recommendation and review posted by sam
Shirley Ma C5/C6 Spinal Cord Injury on the Passive Gait Trainer @ Beyond The Chair – Video
Shirley Ma C5/C6 Spinal Cord Injury on the Passive Gait Trainer @ Beyond The Chair
The Passive Gait Trainer produces a movement that mimics the natural gait pattern in an upright position.From:beyondthechairtexasViews:0 0ratingsTime:00:21More inNonprofits Activism
Follow this link:
Shirley Ma C5/C6 Spinal Cord Injury on the Passive Gait Trainer @ Beyond The Chair - Video
Recommendation and review posted by sam
Christmas Cash Draw 2012 – Video
Christmas Cash Draw 2012
On December 18th, 2012 The Canadian Paraplegic Association NL Foundation drew the winning number for the 2012 Christmas Cash Draw: Winning Numbers Winning # for $10000 is 33942 Winning # for $5000 is 13777 5 Prizes of $200 Winning # #39;s for $200 are as follows: 18822 25750 13999 23266 02836 Thank you so much for your support and Merry Christmas from the Board of Directors and Staff of Spinal Cord Injury Newfoundland and Labrador!From:CanParaplegicNLViews:2 0ratingsTime:03:20More inNonprofits Activism
Visit link:
Christmas Cash Draw 2012 - Video
Recommendation and review posted by sam